Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of nintedanib in systemic sclerosis-associated interstitial lung disease
NL-OMON53112Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nintedanib in pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD), sponsored by Boehringer Ingelheim. Primary endpoint: Incidence of overall adverse events. Started Dec 2017; status: active, not recruiting.
02
Drugs
nintedanib
03
Conditions
pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)
Beyond the preview
Go deeper on NL-OMON53112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53112.